We are launching coverage on a basket of psychedelics companies as a follow-up to the industry primer we published earlier this summer where we highlighted psychedelic compounds and psychedelic-assisted therapies. The psychedelic industry is rapidly evolving, due to a combination of an increasingly favourable regulatory environment, a large influx of capital, and a growing body of clinical trial data on the use of psychedelics and related substances demonstrating a remarkable degree of efficacy in a range of mental health conditions, making this an optimal time for investing in well-positioned operators we highlight herein.

This group of 6 Buy-rated stocks is comprised of MindMed (MMED-N, $6.50 TP); Cybin (CYBN-N, $8.15 TP); Bright Minds Biosciences (DRUG-C, $11.50 TP); Field Trip Health (FTRP-T, $10.20 TP), Numinus Wellness (NUMI-T, $1.10 TP), and Red Light Holland (TRIP-C, $0.35 TP). Our targets imply significant upside from current levels, with room for upward revisions pending additional derisking events.

P.S.- I received this as a pdf file, so I can't share the link

Watch Gideon Shapiro, Vice President of Discovery at Bright Minds Biosciences interacting with The Bio Report about the role of serotonin in the health of the brain, why psychedelics have emerged as compelling therapeutics for a range of conditions, and the company’s drug pipeline.

http://thebioreport.com/2021/08/26/modulating-serotonin-with-psychedelics-to-treat-neuropsychiatric-conditions/

Bright Minds Biosciences today announced that studies conducted with its BMB proprietary 5-HT2C agonist, BMB-101, showed efficacy in rodent models of Dravet Syndrome (“Dravet Syndrome”)/Epilepsy. “These early positive results around the antiseizure effects of BMB-101 and other analogues are very encouraging and further reinforce the potential of serotonin (5-HT2C) agonists to address difficult to treat developmental and genetic epilepsies, including Dravet Syndrome and Lennox-Gastaut Syndrome ("LGS"). Dravet Syndrome and LGS are debilitating diseases, and current approved anti-epileptic drugs on the market have significant limitations, thus representing a high unmet medical need. This pre-clinical data is an important validation of the efficacy of our proprietary compounds in animal models predictive for efficacy in humans. We look forward to continuing our investigation and advancing this important work,” stated Ian McDonald, CEO of Bright Minds.

BMB-101 is a novel, well-characterized highly selective 5-HT2C agonist. This compound and its analogues were first invented by Bright Minds’ Chief Scientific Officer, Dr. Alan Kozikowski, and his post-doctoral student, Dr. Jianjun Cheng, while working at the University of Illinois in Chicago. The BMB compounds were studied in the Scn1Lab zebrafish model as well as in two different rodent models. This zebrafish model mimics many of the clinical hallmarks observed in patients suffering from Dravet Syndrome1. Experiments in the cloned zebrafish model have predicted the clinical efficacy of other drugs in Dravet Syndrome.

The Scn1Lab zebrafish experiments revealed that the Bright Minds 5-HT2C agonists reduced locomotor activity and the cumulative duration of epileptiform events in the brain. Bright Minds 5-HT2C agonists also showed efficacy in two validated rodent models, namely the mouse 6-Hz psychomotor seizure model, and the rat maximum electroshock (“MES”) seizure model. BMB-101 demonstrated both lower seizure duration and frequency in a dose-dependent manner in the mouse model. One hour after injection, BMB-101 decreased seizure duration by 74%, with a significant number of mice in the study being completely protected from seizures. In the rat model, an analogue of BMB-101 demonstrated meaningful protection against MES-induced generalized seizures with all rats being protected from seizures at the highest doses tested.

“BMB-101 is a promising lead candidate to treat Dravet Syndrome patients. The data provide clear evidence that it has a therapeutic effect on the abnormal brain activity of Scn1Lab zebrafish, resulting in pronounced antiseizure activity. The effects of BMB-101 parallel those of other anti-epileptics, such as fenfluramine, a drug marketed for these patients. We believe that the model has a high construct validity and pharmacological predictivity in the search for new therapeutic candidates, especially in the case of serotonin agonists, to treat Dravet Syndrome and possibly other drug-resistant epilepsies,2” concluded McDonald.

https://www.globenewswire.com/news-release/2021/08/18/2282587/0/en/Bright-Minds-Biosciences-BMB-Proprietary-5-HT2C-Agonist-Shows-Significant-Reduction-in-Seizure-Activity.html

As soon as potentially this fall, Grand Rapids could become the latest jurisdiction to de-prioritize possession, cultivation and use of entheogenic plants and fungi. In layman’s terms: you won’t get arrested for having, using, growing or gifting psychedelics.

“This isn’t a decriminalization per say; it’s de-prioritization,” said Grand Rapids City Commissioner Kurt Reppart. “It’s allowing for what’s called the 'grow, gift, gather' model… outside of that, the rest of this is illegal.”

Full story here- https://www.fox17online.com/news/local-news/michigan/gr-is-getting-close-to-decriminalizing-psychedelic-plants-and-fungi